Ascentage Pharma Group International - American Depository Shares (AAPG)
AAPG moved a median of -0.04% 30 minutes after news, and -0.59% by the close. How AAPG actually reacts to news — the realized, point-in-time move the market made, measured across 82 labeled events over the last three years with zero look-ahead.
AAPG’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 25% | 40 |
| 30-min | -0.04% | 31% | 62 |
| 60-min | -0.05% | 44% | 69 |
| to close | -0.59% | 38% | 81 |
| Middle 50% of AAPG reactions | -1.34% to +1.09% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 82 |
Half of all Ascentage Pharma Group International - American Depository Shares news events land between -1.34% and +1.09% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AAPG moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AAPG's baseline. Nothing else.
Recent AAPG events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K ASCENTAGE PHARMA GROUP For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | +0.83% | +1.52% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Sep 28 | SEC filing · Form 6-K | SEC EDGAR | +4.29% | -0.20% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Sep 17 | SEC filing · Form 6-K | SEC EDGAR | — | -0.13% | |
| Ascentage Pharma to Participate in Four Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +1.02% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Aug 20 | SEC filing · Form 6-K | SEC EDGAR | -0.56% | -3.72% | |
| Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.56% | -3.72% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.55% | |
| Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit | Press release | GlobeNewswire | — | +0.48% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | — | +0.48% | |
| Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 | Press release | GlobeNewswire | — | -0.62% | |
| CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 | Press release | GlobeNewswire | — | -0.62% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Aug 05 | SEC filing · Form 6-K | SEC EDGAR | — | -0.62% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -3.13% | -4.25% | |
| Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer | Press release | GlobeNewswire | -3.13% | -4.25% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jul 27 | SEC filing · Form 6-K | SEC EDGAR | -0.00% | -1.43% | |
| Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 | Press release | GlobeNewswire | +0.00% | +3.11% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jul 20 | SEC filing · Form 6-K | SEC EDGAR | — | -4.52% | |
| Form F-3ASR ASCENTAGE PHARMA GROUP | SEC filing · Form F-3ASR | SEC EDGAR | — | -4.52% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.72% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | — | +2.40% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | +1.09% | -3.51% | |
| Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress | Press release | GlobeNewswire | +1.09% | -3.51% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | -0.34% | -0.28% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | — | +0.47% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | — | -3.49% | |
| Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 | Press release | GlobeNewswire | — | -3.49% | |
| Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 | Press release | GlobeNewswire | — | -3.49% | |
| Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 | Press release | GlobeNewswire | — | -3.49% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: May 27 | SEC filing · Form 6-K | SEC EDGAR | +0.16% | +4.19% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: May 28 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.77% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: May 22 | SEC filing · Form 6-K | SEC EDGAR | — | +4.79% | |
| Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | Press release | GlobeNewswire | — | +4.79% | |
| Form 6-K ASCENTAGE PHARMA GROUP For: May 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +6.85% | |
| Ascentage Pharma to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | — | -1.72% | |
| Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress | Press release | GlobeNewswire | +0.00% | +6.85% | |
| Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 | Press release | GlobeNewswire | — | -2.22% | |
| Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting | Press release | GlobeNewswire | +0.00% | -0.11% | |
| Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates | Press release | GlobeNewswire | — | -3.20% | |
| Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 | Press release | GlobeNewswire | +0.00% | +0.13% | |
| Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 | Press release | GlobeNewswire | +0.00% | +0.41% | |
| Ascentage Pharma to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | — | +0.97% | |
| Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +0.00% | -3.12% | |
| Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 | Press release | GlobeNewswire | -1.41% | +2.17% | |
| Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | — | -2.36% | |
| Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 | Press release | GlobeNewswire | +0.00% | +2.13% | |
| Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | — | -4.10% | |
| ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% | Press release | GlobeNewswire | +1.66% | -2.05% | |
| ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP | Press release | GlobeNewswire | +1.66% | -2.05% | |
| ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment | Press release | GlobeNewswire | +1.66% | -2.05% | |
| ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances | Press release | GlobeNewswire | — | -3.06% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AAPG section they belong to.
Where else AAPG is measured.
AAPG earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ascentage Pharma Group International - American Depository Shares's median reaction calculated?
Every labeled AAPG news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 82 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 31% of AAPG's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AAPG's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.